380 completed. 380 Phase 3, 86 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 380 | Completed 380 |
| Phase 2 | 86 | Completed 86 |
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss GZR18 injection, Placebo - Overweight or Obesity | Phase 3 | Completed | Gan & Lee Pharmaceuticals. | 224 | 2026-01-22 | 2026-11-10 |
| Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes Dulaglutide, Semagludtide, Tirzepatide - Non-diabetec Obesity, Obesity (Disorder) | Phase 3 | Completed | Zagazig University | 150 | 2025-11-14 | 2026-09-22 |
| Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician - Obese Diabetics, Obese Non Diabetic | Phase 3 | Completed | Zagazig University | 159 | 2025-10-18 | 2026-09-15 |
| A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity HRS-7535 Tablets, HRS-7535 Placebo Tablets - Overweight, Obesity | Phase 3 | Completed | Shandong Suncadia Medicine Co., Ltd. | 556 | 2025-04-10 | 2026-07-27 |
| A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects TQF3510 (Semaglutide Injection), Wegovy® - Obesity | Phase 3 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 408 | 2025-03-20 | 2026-09-25 |
| Semaglutide in Women With Polycystic Ovary Syndrome and Obesity Metformin with Semaglutide - Polycystic Ovary Syndrome (PCOS) Women, Obesity | Phase 2 / Phase 3 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 31 | 2025-01-01 | 2026-10-07 |
| A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects GZR18, Placebo - Obesity/Overweight | Phase 3 | Completed | Gan & Lee Pharmaceuticals. | 640 | 2024-12-30 | 2026-11-12 |
| A Research Study of VCT220 in Adult Chinese Participants With Obesity VCT220, Placebo - Obesity, Overweight | Phase 3 | Completed | Vincentage Pharma Co., Ltd | 840 | 2024-12-24 | 2026-09-16 |
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) mibavademab - Generalized Lipodystrophy | Phase 3 | Completed | Regeneron Pharmaceuticals | 9 | 2024-12-16 | 2026-07-29 |
| A Study of HS-20094 in Chinese Adults With Overweight or Obesity HS-20094 injection, Placebo injection - Overweight, Obesity | Phase 3 | Completed | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 604 | 2024-11-16 | 2026-06-08 |
| A Study of BGM0504 Injection in Participants With Obesity or Overweight 5 mg BGM0504 injection, 10 mg BGM0504 injection administered subcutaneously (SC) once a week, 15 mg BGM0504 injection - Overweight or Obesity | Phase 3 | Completed | BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | 652 | 2024-10-29 | 2026-10-15 |
| A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Orforglipron, Placebo - OSA, Overweight or Obesity | Phase 3 | Completed | Eli Lilly and Company | 712 | 2024-10-22 | 2026-09-14 |
| Open-Label Extension Study of Setmelanotide Setmelanotide - Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 28 | 2024-10-21 | 2026-07-15 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriasis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 281 | 2024-09-30 | 2026-06-17 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriatic Arthritis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 279 | 2024-09-24 | 2026-05-13 |
| A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Orforglipron, Placebo - Obesity, Overweight | Phase 3 | Completed | Eli Lilly and Company | 376 | 2024-09-13 | 2026-06-04 |
| A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight Cagrilintide, Semaglutide, Placebo - Obesity | Phase 3 | Completed | Novo Nordisk A/S | 300 | 2024-06-24 | 2026-05-05 |
| Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) Essential Amino Acid Supplement by Amino Co, Placebo - Hepatic Steatosis, NAFLD | Phase 3 | Completed | University of Colorado, Denver | 31 | 2024-06-18 | 2026-08-31 |
| To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese HRS9531 injection, Placebo - Overweight or Obesity | Phase 3 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 567 | 2024-05-13 | 2025-07-11 |
| A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) Survodutide, Placebo - Obesity, Non-Alcoholic SteatoHepatitis (NASH) | Phase 3 | Completed | Boehringer Ingelheim | 218 | 2024-04-02 | 2026-04-30 |
Showing 20 of 380. Sign in to see all of them.
Obesity (336) · Diabetes Mellitus, Type 2 (48) · Weight Loss (35) · Motor Activity (31) · Hypertension (24) · Insulin Resistance (19) · Diabetes Mellitus (18) · Cardiovascular Diseases (17) · Metabolic Syndrome (17) · Nutrition Disorders (17) · Obesity, Morbid (15) · Binge-Eating Disorder (12) · Dyslipidemias (12) · Prader-Willi Syndrome (10)
Nutritional and Metabolic Diseases (380) · Overnutrition (380) · Pathological Conditions, Signs and Symptoms (369) · Signs and Symptoms (368) · Nutrition Disorders (363) · Body Weight (361) · Metabolic Diseases (103) · Glucose Metabolism Disorders (92) · Endocrine System Diseases (79) · Diabetes Mellitus (50) · Body Weight Changes (37) · Behavior (36) · Hyperinsulinism (35) · Nervous System Diseases (32)
semaglutide (37) · Exercise (18) · Tirzepatide (15) · Liraglutide (14) · Metformin (13) · Diet (10) · Topiramate (9) · Rimonabant (8) · sibutramine (8) · bupropion hydrochloride, naltrexone hydrochoride drug combination (7) · setmelanotide (7) · Exenatide (6) · BI 456906 (5) · Diet, Reducing (5) · cagrilintide (5)
Novo Nordisk A/S (35) · Eli Lilly and Company (21) · Yale University (13) · Sanofi (8) · Boehringer Ingelheim (7) · Mayo Clinic (7) · Rhythm Pharmaceuticals, Inc. (7) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6) · Abbott (5) · Orexigen Therapeutics, Inc (5) · The Miriam Hospital (5) · Assistance Publique - Hôpitaux de Paris (4) · University of Colorado, Denver (4) · VIVUS LLC (4)
United States (197) · Canada (43) · France (36) · Germany (36) · United Kingdom (35) · Spain (32) · China (31) · Puerto Rico (23) · Brazil (22) · Mexico (22) · Italy (20) · Japan (20) · Taiwan (20) · Australia (19) · South Korea (19)
David Meeker, MD (7) · Craig Peterson (4) · Dennis T Villareal, MD (4) · Allison B. Goldfine, MD (3) · Barbara Grube, MD (3) · Carlos M Grilo, Ph.D. (3) · Kathleen Jablonski, PhD (3) · Kishore Gadde, MD (3)
PMID 27482610, PMID 27817208, PMID 28386912, PMID 28950422, PMID 30122305, PMID 38698650, PMID 39226070, PMID 23661689, PMID 26418188, PMID 27206567, PMID 27659698, PMID 27888609, PMID 28455281, PMID 28473337, PMID 35724304, PMID 36801984, PMID 40717199, PMID 41187013, PMID 41537305, PMID 41885866, PMID 42821228, PMID 26744025, PMID 26833744, PMID 27116910, PMID 27193270, PMID 27804269, PMID 28462892, PMID 33137293, PMID 33567185, PMID 33667417, PMID 36200477, PMID 37605636, PMID 37919617, PMID 38671361, PMID 39222642, PMID 39316288, PMID 39800653, PMID 40512543, PMID 40980163, PMID 41640675, PMID 42014131, PMID 42348366, PMID 12439645, PMID 15486569, PMID 15536230, PMID 15836887, PMID 16018851, PMID 16291982, PMID 16478899, PMID 16636211
2017 (7), 2023 (6), 2008 (3), R01DK049587 (3), R01DK114075 (3), R01DK126637 (3), 2014 (2), 2018 (2), R01AG025501 (2), R18DK083248 (2), U01DK074556 (2), 1RC1DK086132 (1), 2015 (1), 2016 (1), 2019 (1)